PSA testing patterns in a large Swedish cohort before the implementation of organized PSA testingShow others and affiliations
2020 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 54, no 5, p. 376-381Article in journal (Refereed) Published
Abstract [en]
Background: Organized PSA testing for asymptomatic men aged 50-74 years will be implemented in Sweden to reduce opportunistic testing in groups who will not benefit. The aim of this study was to describe the opportunistic PSA testing patterns in a Swedish region before the implementation of organized PSA testing programs.
Method: We included all men in the Uppsala-orebro health care region of Sweden who were PSA tested between 1 July 2012 and 30 June 2014. Information regarding previous PSA testing, prostate cancer diagnosis, socioeconomic situation, surgical procedures and prescribed medications were collected from population-wide registries to create the Uppsala-orebro PSA cohort (UPSAC). The cohort was divided into repeat and single PSA testers. The background population used for comparison consisted of men 40 years or older, living in the Uppsala-orebro region during this time period.
Results: Of the adult male population in the region, 18.1% had undergone PSA testing. Among men over 85 years old 21% where PSA tested. In our cohort, 62.1% were repeat PSA testers. Of men with a PSA level <= 1 mu g/l 53.8% had undergone repeat testing. Prostate cancer was found in 2.7% and 4.8% of the repeat and single testers, respectively.
Conclusion: Every fifth man in the male background population was PSA tested. Repeated PSA testing was common despite low PSA values. As repeated PSA testing was common, especially among older men who will not be included in organized testing, special measures to change the testing patterns in this group may be required.
Place, publisher, year, edition, pages
Taylor & Francis, 2020. Vol. 54, no 5, p. 376-381
Keywords [en]
PSA, organized PSA testing, screening, prostate cancer, Uppsala-orebro PSA cohort
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:oru:diva-85226DOI: 10.1080/21681805.2020.1797871ISI: 000555212800001PubMedID: 32734806Scopus ID: 2-s2.0-850889551452-s2.0-85088955145OAI: oai:DiVA.org:oru-85226DiVA, id: diva2:1461962
Funder
Swedish Cancer Society, CAN2016/466 CAN2014/1275
Note
Funding Agency:
Swedish Prostate Cancer Association
2020-08-282020-08-282025-02-18Bibliographically approved